|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
Moving Biotech Products from CBER to CDER: A Work in Progress
A slow, steady process of transitioning biologicals has allayed industry concerns.
Advertisement
Articles in this issue
over 19 years ago
Analytical Instrument Qualificationover 19 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?over 19 years ago
Team Effortover 19 years ago
Rated PG: Pharmaceutical Guidance Suggestedover 19 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionover 19 years ago
New Climateover 19 years ago
2006: A Regulatory Odysseyover 19 years ago
CDER?s Division of Post-Marketing Evaluation for Quality AssessmentNewsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
The Scientist’s Value in the Age of Automation
2
Chromatography-Enabled Detection of Respiratory Medications in Wastewater
3
Green Stabilizers in Nitrocellulose Propellants: VOC Fingerprinting of Accelerated Aging by HS-SPME–GC×GC–TOF-MS
4
Streamlined Method Development for Efficient and Reliable Lipid Nanoparticle Analysis
5
